# Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity

> **NCT04519164** · PHASE4 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 79 (actual)

## Conditions studied

- Metabolic Syndrome
- Hypertension
- Overweight and Obesity

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Chlorthalidone with potassium chloride

## Key facts

- **NCT ID:** NCT04519164
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2025-09-17
- **Final completion:** 2025-09-17
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04519164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04519164, "Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04519164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*